Total
0
Shares
Image Sourced ShutterStock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Immutep has been granted a European patent to protect intellectual property relating to cancer and autoimmune disease treatment.
  • The patent protects the combination of eftilagimod alpha (efti) with a chemotherapy agent.
  • Efti a lead active immunotherapy candidate currently in late-stage clinical development.

Biotech company Immutep Limited has been granted a new European patent to protect its intellectual property regarding specific treatments of cancer and other autoimmune diseases.

The patent, which is called “Combined Preparations for the Treatment of Cancer” and was granted by the European Patent Office, concerns Immutep’s lead active immunotherapy candidate eftilagimod alpha — known more simply as efti.

The patent also regards a chemotherapy agent, which Immutep says is either a platinum-based anti-neoplastic agent, which would generally be used to treat bowel cancer or lung cancer, or a topoisomerase I inhibitor, which would usually treat ovarian or lung cancer.

Efti is currently in late-stage clinical development for the treatment of cancer, and the patent protects the combination of efti with one of the chemotherapy agents.

Immutep Chief Scientific Office and Chief Medical Officer Dr Frédéric Triebel says this patent provides protection in Europe for a range of chemo-immunotherapies which use efti.

“This new patent is important because platinum-based chemotherapy agents and topoisomerase I inhibitors continue to be commonly used forms of chemotherapy,” Frédéric said.

“In addition, the past couple of years has seen, for the first time, the marketing approval and adoption of first or second line combinations of chemotherapy and active immunotherapies for the treatment of advanced solid tumours,” he said.

Immutep is a global biotechnology company with operations in Europe, Australia, and the US, and a focus on developing products for the treatment of cancer and other autoimmune diseases.

Dr Triebel made a breakthrough for Immutep in 1990 when he discovered the Lymphocyte Activation Gene-3 (LAG-3) protein, which is involved in human immune system regulation.

Immutep is using its industry-leading knowledge of LAG-3 and development of LAG-3 products to investigate the LAG-3 immune control mechanism in the treatment of cancer and autoimmune disease.

IMM by the numbers
More From The Market Herald
Biogene Technology (ASX:BGT) - CEO, Richard Jagger

" Bio-Gene (ASX:BGT) shares close green on new commercial deal

Bio-Gene Technology (BGT) has executed a licence and development agreement with Evergreen Garden Care.
Beam Communications (ASX:BCC) - Chairman, Simon Wallace

" Beam Communications (ASX:BCC) receives orders for 12,000 ZOLEO units

Beam Communications (BCC) has received orders for 12,000 extra ZOLEO devices manufactured under its joint venture entity.
Botanix Pharmaceuticals (ASX:BOT) - President & Executive Chairman, Vince Ippolito

" Botanix Pharmaceuticals (ASX:BOT) progresses clinical programs

Botanix Pharmaceuticals (BOT) progressed a number of clinical programs during the September quarter.
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham

" Recce Pharmaceuticals (ASX:RCE) receives ethics approval to begin R327 trial

Recce Pharmaceuticals (RCE) has received Human Research Ethics Committee (HREC) approval to begin its phase one intravenous (IV) trial of RECCE327 (R327).